This article reviews current concepts regarding the clinical and scientific rationale for the combined use of glucocorticosteroids and beta-2-adrenoreceptor (b2AR) agonists in the treatment of childhood asthma.
Introduction
Reversible airflow obstruction, bronchial hyperresponsiveness, and airway inflammation are the characteristic features of asthma [1] . Notwithstanding these common features, there exist phenotypic differences between children and adults with asthma [2 ]. Specifically, childhood asthma is not a homogenous entity and its expression reflects the manifestation of various pathophysiological processes. Accordingly, viral infections, allergic airway inflammation, and exposure to a host of aeroallergens and pollutants can evoke airway hyperresponsiveness and exacerbations of asthma via different mechanisms [3] [4] [5] . Interestingly, despite these varied causal mechanisms, glucocorticosteroids and beta-2-adrenoreceptor (b2AR) agonists remain the mainstay of therapy to prevent and reverse asthma exacerbations in children [1] . In this review, we discuss the latest insights into the use of glucocorticosteroids and b2AR agonists to treat childhood asthma, with emphasis placed on the clinical efficacy, safety, and molecular mechanisms underlying the therapeutic benefit of the combined use of these medications.
Glucocorticosteroids and the management of preschool wheezing and asthma: the importance of asthma phenotyping Wheezing in early life needs to be carefully evaluated in order to decide the best strategy of treatment. In this regard, a phenotypical differentiation of preschool wheezing based on symptom pattern has been recently proposed by the European Respiratory Society (ERS) Task Force [6 ] . The ERS Task Force divides preschool wheezing into either episodic (viral) or multiple-trigger wheezing. The major advantage of this phenotypical distinction is that it allows for a rational approach to treatment planning. This is particularly true when the clinician is deciding how to treat episodic viral-induced wheezing in preschool children. In this context, a recent meta-analysis [7 ] concluded that infants and preschool children with recurrent wheezing or asthma had fewer exacerbations and improved lung function and symptoms during treatment with inhaled corticosteroids (ICS). This evidence notwithstanding, when viral-induced wheezing is evaluated in individual studies, the evidence is less convincing. A double-blind, randomized, placebocontrolled trial conducted by Panickar et al. [8 ] found no significant benefit of oral prednisolone in preschool children hospitalized with acute virus-induced wheezing when compared with placebo. These results are similar to those of a previous study [9] that reported that there is no clear benefit of a short course of parent-initiated oral prednisolone for viral wheezing in children aged 1-5 years.
Within the context that ICS may not alter the natural history of preschool wheezing [10-12], the use of ICS in infants and children with episodic viral-induced wheezing requires careful consideration of benefits and potential side effects. This trade-off was recently demonstrated by Ducharme et al. [13 ] in a study that evaluated the use of a high dose of fluticasone in preschool-age children with moderate-to-severe virus-induced wheezing. Although the high-dose ICS treatment reduced the use of rescue oral corticosteroids compared with placebo, it was also associated with a decreased rate of growth with respect to both height and weight. Given the possibility of these unfavorable side effects with prolonged high-dose ICS treatment, there is increasing interest in exploring alternatives to the management of viral wheezing in this age group. In this connection, recent clinical trials [14, 15] have reported that leukotriene receptor antagonists (LTRAs) may be effective for the treatment of viral-induced wheezing in preschool children, but that the greatest effect of LTRA use is in patients with a negative family history of asthma and a serum immunoglobulin E less than 130 [14] . These results suggest that LTRA may not be as effective an alternative for children with atopic phenotypes, who represent a group of patients in whom ICS appear to be highly effective [16 ] .
Inhaled glucocorticosteroids: the first line of pediatric asthma management
Once the diagnosis of asthma has been established, there is little controversy that glucocorticosteroids are the most effective therapy to control asthma symptoms and reduce moderate-to-severe exacerbations. The most recent asthma guidelines from the Expert Panel Report 3 (EPR-3) [1] are the first to provide evidence-based recommendations for the management of asthma in children 0-4 years of age and 5-11 years of age, and youths above 12 years of age. The EPR-3 concludes that ICS are the most potent and consistently effective long-term control medications for patients who have persistent asthma in all age groups [1] . More recent studies have further supported this notion. The inhaled Steroid Treatment As Regular Therapy in Early Asthma study [17 ] , a 5-year follow-up of a large cohort of 7241 combined pediatric and adult patients with recent-onset, mild-persistent asthma, has demonstrated that early intervention with inhaled budesonide is associated with improved asthma control and a lesser need for additional asthma medications. These results complement the findings of previous randomized, double-blind clinical trials in children such as the Childhood Asthma Management Program study [18] and the Prevention of Early Asthma in Kids (PEAK) study [19] , both of which demonstrated that ICS are effective in preventing asthma exacerbations in children above 2 years of age.
Another important consideration pertaining to chronic ICS therapy in children is the potential for adverse side effects, particularly from the use of high doses [13 ] . In this regard, there has been an increasing interest in determining which clinical criteria can best predict the optimal response to ICS and, therefore, help to identify the most appropriate high-risk children who may benefit most from maintenance ICS therapy. A recent multivariable analysis [16 ] of the participants in the PEAK trial found more favorable responses to ICS in preschool children with an emergency department visit or hospitalization for asthma within the last year, children with aeroallergen sensitization, boys, and white participants. In addition, the Pediatric Asthma Controller Trial (PACT) [20 ] reported that, in children with mild-tomoderate persistent asthma, the presence of increased exhaled nitric oxide (eNO) levels, low PC20 methacholine values, and a parental history of asthma predict the best long-term outcomes with ICS therapy when compared with treatment with LTRAs alone.
Use of beta-2-adrenoreceptor agonists alone and in combination with inhaled glucocorticosteroids b2AR agonists are commonly used medications in the management of asthma. Intermittent use of inhaled short-acting b2AR agonists (SABAs) is the drug of choice for treating acute asthma symptoms and exacerbations, and for preventing exercise-induced bronchospasm [1]. Alternatively, the daily use of long-acting b2AR agonists (LABAs) carries the potential risk of worsening of the asthmatic condition [21] . This was confirmed in a large clinical study [22] , the Salmeterol Multicenter Asthma Research Trial, which reported that daily treatment with salmeterol resulted in an increased risk of asthma-related deaths in patients when compared with placebo. Importantly, LABAs reportedly have a beneficial and safe role in the management of asthma when these agents are used in combination with ICS. In this regard, it is particularly noteworthy that Weatherall et al. [23 ] recently conducted a meta-analysis of 215 randomized, controlled studies, encompassing a total of 106 575 participants, to evaluate the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. This meta-analysis concluded that salmeterol monotherapy in asthma increases the risk of asthma mortality but that this risk is ablated with concomitant ICS therapy.
There is also recent evidence suggesting that the combination of LABA and ICS may be more effective than the use of high-dose ICS therapy alone in children with uncontrolled asthma. The VIAPAED study group [24 ] has published a multicenter study that compared the efficacy and safety of doubling the dose of ICS with that of adding a LABA to the ICS. This study found that, in children and adolescents aged 4-16 years with uncontrolled asthma, treatment with fluticasone and salmeterol (100/50 mg) resulted in higher peak flow rates, fewer asthma symptoms, and better overall asthma control when compared with 8 weeks of treatment with double-dose fluticasone (200 mg twice daily) [24 ] . De Blic et al. [25 ] reported similar results in another recent multicenter trial, which reported that ICS-LABA treatment was associated with better lung function and asthma control when compared with 12 weeks of double-dose ICS therapy in children with uncontrolled asthma. Both these clinical trials demonstrated that either ICS and LABA or double ICS therapy was well tolerated, and no serious adverse events were reported. Finally, a recent metaanalysis [26 ] of 25 randomized controlled trials suggested that the addition of LABA to ICS is superior to increased dose of ICS in children with persistent asthma. As previously established in adult patients [27] [28] [29] [30] [31] , these new pediatric data suggest that the combination of ICS-LABA may provide a greater benefit than high doses of ICS alone in children with uncontrolled asthma.
New combined therapies: a single inhaler for maintenance and relief
The reported concerns about the safety of LABA preparations have motivated the development of new combinational therapies, including inhalers that contain an ICS together with a quick-acting b2AR agonist. These combined inhalers may be a convenient alternative to prevent and treat asthma exacerbations [32 ] . Papi et al. [33] recently investigated whether symptom-driven use of a combination of beclomethasone and albuterol in a single inhaler could be as effective as the regular use of inhaled beclomethasone and the as-needed use of albuterol in adult patients with mild asthma. The study demonstrated that symptom-driven use of a single inhaler containing beclomethasone/albuterol is as effective as the regular use of beclomethasone in patients with mild asthma. Moreover, the group treated with the beclomethasone/ albuterol single inhaler had a lower 6-month cumulative dose of corticosteroid compared with the patients who used inhaled beclomethasone alone [33] . The latter finding may be of particular significance in the pediatric population given that cumulative corticosteroid levels may be associated with unfavorable side effects (e.g., impaired growth development).
Another large clinical trial conducted by O'Byrne et al. [34] reported that use of a single inhaler containing ICS and a quick-acting LABA (budesonide/formoterol; 80/4.5 mg) for both asthma maintenance and relief significantly reduced the risk and rate of severe asthma exacerbations, as well as the need for systemic steroids, when compared with the traditional use of a fixed dose of ICS. Importantly, in this large study, which included 2760 patients aged 4-80 years with moderate-severe asthma, the significant reduction in severe exacerbations was consistent in children, adolescents, and adults [34] . Furthermore, children (4-11 years) receiving the combined inhaler for maintenance and relief had significantly better growth (adjusted mean difference in growth of 1.0 cm; 95% confidence interval, 0.3-1.7; P ¼ 0.0054) than those in the budesonide alone group. Notwithstanding this evidence, the potential benefits of the combined single inhaler approach are less clear in preschool children with wheezing. In this regard, a recent multicenter trial [35] conducted in 276 preschool children aged 1-4 years with frequent wheezing (>3 episodes in the previous 6 months) by the BEclomethasone and Salbutamol Treatment for Children Study Group showed that the use of regular inhaled glucocorticoid was superior to combined therapy with respect to maintenance and symptom relief. Similarly to previous studies, the cumulative dose of beclomethasone was lower in the beclomethasone-salbutamol combination treatment group. Taken together, the information given by these clinical trials suggests that additional studies are clearly needed to further evaluate the effectiveness of these new combined inhalers in the management of childhood asthma. In addition, future investigations should be designed to specifically evaluate the efficacy and safety of these therapies in the different phenotypes of asthma in infants and children.
New insights into beta-2-adrenoreceptor agonists: understanding their proasthmatic potential
Although b2AR agonists are highly effective for the acute relief of bronchoconstriction, the deleterious effects of their chronic use in asthma have raised important questions about the pathobiology of the disease. Previous studies [36] [37] [38] have reported that prolonged b2AR stimulation induces not only 'tolerance' to the bronchodilatory effect of b2AR agonists but also enhanced reactivity to bronchoconstrictor agents. Recent investigations have demonstrated that sustained exposure to b2AR agonists [39 ] or other cyclic AMP (cAMP) elevating agents [40] induces proasthmatic changes in airway smooth muscle (ASM) contractility and relaxation that are mediated by upregulated phosphodiesterase 4 (PDE4) activity. These observations are consistent with previous evidence that implicates upregulated PDE4 activity in mediating airway hyperreactivity (AHR) in asthmatic patients [41] and in animal models of allergic asthma [41] [42] [43] [44] [45] [46] . Furthermore, the link between b2AR signaling and the pathogenesis of asthma has been recently extended. For instance, Nguyen et al. [47] described that, in a murine model of asthma, b2AR signaling is required for the full development of the asthmatic phenotype. There was a significant decrease in antigen-driven AHR and airway inflammation seen in b2AR-null mice and in animals that received chronic treatment with nadolol, a b2AR blocker with inverse agonist properties. In addition, Hanania et al. [48] recently published the first open-label study in mild corticosteroid-naive asthmatic patients to evaluate the effects of nadolol (10-40 mg) on AHR. This 'proof of concept' study showed that, after an expected acute worsening, chronic nadolol treatment (9 weeks) improved AHR in eight of 10 patients, as evidenced by a dosedependent increase in the PC20 to methacholine. Taken together, these observations suggest that there may be a b2AR-dependent signaling pathway that evokes airway hyperresponsiveness and, thereby, plays a critical role in the generation of the asthmatic state.
New insights into the molecular interactions of glucocorticosteroids and beta-2adrenoreceptor agonists in airway smooth muscle
There are also new insights into the mechanisms involved in mediating the beneficial effects of the combination of glucocorticosteroids and b2AR agonists [49 ] in the treatment of asthma. Previous investigations [27] [28] [29] [30] have established that this combinational therapy is associated with superior anti-inflammatory effect and better asthma control. Consequences of the molecular interaction of glucorticosteroids and b2AR agonists include both enhanced glucocorticoid receptor-mediated responses [50] [51] [52] and augmented b2AR transcription and function [52] [53] [54] . Moreover, new data suggest that there are also complementary interactions between b2AR and glucocorticosteroids signaling in regulating ASM contractility and relaxation. In this context, Cooper and Panettieri [55] reported that glucocorticosteroids completely reverse b2AR tolerance in isolated human small airways exposed to a SABA and, more recently, we demonstrated that glucocorticoids protect ASM from the proasthmatic effects of prolonged LABA exposure on ASM contractility and relaxation [56 ] . The mechanism underlying the latter protective action of glucocorticosteroids on ASM function was found to involve glucocorticoid-mediated inhibition of proasthmatic signaling via the mitogen-activated protein kinase (MAPK) signaling pathway due to the induction of MAPK phosphatase-1 [56 ] . In light of this new evidence, future interventions targeted at this mechanism may yield new therapeutic approaches to improve asthma control.
Conclusion
Although glucocorticosteroids and b2AR agonists remain the first line of therapy for asthma in children and adults, special consideration must be given to the use of corticosteroids to treat infants and young children. Some preschool wheezing phenotypes may not obtain significant clinical benefit, and there are potential serious side effects associated with the use of high doses of ICS in this age group. Large clinical studies have shown that combinational therapy involving an ICS together with a b2AR agonist can provide additional clinical benefits in asthma management, and the clinical efficacy of this therapeutic approach has been substantiated by recent newly identified molecular interactions between b2AR and glucocorticosteroids signaling that modulate ASM contractility and relaxation. In addition, new clinical trials have suggested that a single inhaler containing an ICS and a quick-acting b2AR may be a more convenient and equally effective alternative to prevent and treat asthma exacerbations. However, additional large pediatric clinical studies are needed to establish the efficacy and safety of this therapy in children.
